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Rare-Variant Association Analysis:
Study Designs and Statistical Tests
Seunggeung Lee,1 Gonc¸alo R. Abecasis,1 Michael Boehnke,1 and Xihong Lin2,*
Despite the extensive discovery of trait- and disease-associated common variants, much of the genetic contribution to complex traits
remains unexplained. Rare variants can explain additional disease risk or trait variability. An increasing number of studies are underway
to identify trait- and disease-associated rare variants. In this review, we provide an overview of statistical issues in rare-variant association
studies with a focus on study designs and statistical tests. We present the design and analysis pipeline of rare-variant studies and review
cost-effective sequencing designs and genotyping platforms. We compare various gene- or region-based association tests, including
burden tests, variance-component tests, and combined omnibus tests, in terms of their assumptions and performance. Also discussed
are the related topics of meta-analysis, population-stratification adjustment, genotype imputation, follow-up studies, and heritability
due to rare variants. We provide guidelines for analysis and discuss some of the challenges inherent in these studies and future research
directions.Introduction
In the last 8 years, genome-wide association studies
(GWASs) have been extensively used to dissect the genetic
architecture of complex diseases and quantitative traits.1
These studies systematically evaluate common genetic var-
iants, typically with a minor allele frequency (MAF) > 5%.
To date, more than 2,000 disease-associated common var-
iants have been identified through GWASs.2 These dis-
ease-associated variants have provided many new clues
about disease biology, for example, a role for autophagy
in Crohn disease,3 for the complement pathway in age-
related macular degeneration,4 and for the CNS in predis-
position to obesity.5
Despite these discoveries, much of the genetic contribu-
tion to complex traits remains unexplained, even in dis-
eases for which large GWAS meta-analyses have been
undertaken. For example, a GWAS and follow-up analysis
of type 2 diabetes (T2D [MIM 125853]) in >150,000 indi-
viduals identified >70 loci at genome-wide significance
but that explain only ~11% of T2D heritability.6 Likewise,
a GWAS and follow-up analysis in >210,000 individuals
identified ~70 loci associated with Crohn disease, but these
explain only 23% of heritability.7 In general, GWAS loci
have modest effects on disease risk or quantitative trait
variation, and the long process of translating this knowl-
edge into functional understanding or clinical practice is
just beginning.
Several explanations have been proposed for the so-
called problem of ‘‘missing heritability.’’8,9 Because GWASs
focus on the identification of common variants, it is plau-
sible that analyses of low-frequency (0.5% % MAF < 5%)
and rare (MAF < 0.5%) variants could explain additional
disease risk or trait variability. Rare variants are known to
play an important role in human diseases. Many Mende-
lian disorders and rare forms of common diseases are1Department of Biostatistics, University of Michigan, Ann Arbor, MI 48105, U
MA 02115, USA
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theory predicts that deleterious alleles are likely to be rare
as a result of purifying selection,10,11 and indeed, loss-of-
function variants, which prevent the generation of func-
tional proteins, are especially rare.12,13 There is also recent
empirical evidence that low-frequency and rare variants
are associated with complex diseases.14–16 Until recently,
commercial genotyping arrays have largely ignored this
portion of the allele frequency spectrum—because of a
combination of the lack of systematic catalogs of rare vari-
ation to support array design, the fact that genome-wide
surveys of rare variation require many more assays than
current arrays can support, and a sensible initial choice
to focus on common variants.
Over the past several years, rapid advances in DNA
sequencing technologies17 have transformed human and
medical genetics. Sequencing enables more complete
assessments of low-frequency and rare genetic variants
and investigation of their role in complex traits. Next-
generation sequencing (NGS) technologies are high-
throughput parallel-sequencing approaches that now
generate billions of short sequence reads for modest cost.
These short reads are aligned to a reference genome so
that researchers can identify and genotype sites where
sequenced individuals vary. In recent years, the price of
sequencing has fallen dramatically, enabling exome and
whole-genome sequencing (WGS) studies of complex dis-
eases. For example, the NHLBI Exome Sequencing Project
(ESP) has sequenced the exomes of 6,500 individuals to
study genetic contributions to several different traits, the
T2D-GENES project has sequenced exomes for >10,000
T2D-affected and control individuals across five different
ancestry groups, and the UK10K Project has sequenced
the exomes of 6,000 individuals ascertained for various
diseases and traits and the genomes of 4,000 healthySA; 2Department of Biostatistics, Harvard School of Public Health, Boston,
y of Human Genetics. All rights reserved.
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Figure 1. Data-Processing and Analysis
Flow Chart for Sequencing-Based Associa-
tion Studies
Explanations of these steps are given in
Box 1. The following abbreviation is
used: QC, quality control.individuals with detailed physical characteristics. As a
result of these and other projects,13,18 dbSNP now includes
>60 million genetic variants, the large majority of which
are rare.
Although sequencing provides an unparalleled opportu-
nity to investigate the roles of low-frequency and rare var-
iants in complex diseases, detection of these variants in
sequencing-based association studies presents substantial
challenges. First, deep WGS of large numbers of individ-
uals is costly and is likely to remain so in the near future.
In light of this limitation, various alternative strategies,
including targeted sequencing, exome sequencing, low-
depth WGS, and extreme-phenotype sampling, have
been proposed to increase efficiency. As an example, geno-
typing arrays, such as the Illumina and Affymetrix exome
chips, allow investigators to interrogate previously identi-
fied protein-coding variants across a wide range of the
allele frequency spectrum.19
Second, the statistical power of classical single-variant-
based association tests for low-frequency and rare variants
is low unless sample sizes or effect sizes are very large, and
the requisite multiple test corrections are poorly under-
stood. To address these issues, investigators have recently
developed statistical methods specifically configured for
rare-variant association analysis to boost power. These
methods evaluate association formultiple variants in a bio-
logically relevant region, such as a gene, instead of testing
the effects of single variants, as is commonly done in
GWASs.
In this review, we provide an overview of the current
status of sequencing-based association studies and dis-
cuss the statistical issues that arise. We first discuss
strategies for study design, proceed to association testing
and meta-analysis methods for sequencing-based rare-
variant association studies, and conclude with other
important issues, including population-stratification
adjustment, genotype imputation, and the design of
follow-up studies.6 The American Journal of Human Genetics 95, 5–23, July 3, 2014Design Strategies for Rare-Variant
Studies
Sequencing-based association studies
require several data-processing and
-analysis steps, including platform
selection, quality control, choice of
analysis units, assignment of variants
to analysis units with bioinformatic
tools, selection of methods for testing
rare-variant effects, and prioritization
and replication of top signals (Figure 1and Box 1). In this section, we focus on choices of different
sequencing designs and platforms, and we discuss associa-
tion analysis in the next section.
Deep WGS of large numbers of individuals provides the
most informative strategy for association studies of com-
plex traits and diseases. However, the combination of
large-scale WGS and classical epidemiological designs,
such as case-control and cohort studies, is currently
impractical because of the high cost. Several less costly
sequencing strategies have been proposed and used and
are discussed here: low-depth WGS, exome sequencing,
targeted-region sequencing, and rare-variant genotyping
arrays (Table 1). We also discuss extreme-phenotype sam-
pling as an alternative study design.
Low-Depth WGS
Sequencing depth refers to the average number of
reads that cover each base. Owing to the costs associated
with deepWGS of large numbers of individuals, low-depth
WGS has been proposed as a cost-effective alternative.20,21
When sample-preparation costs are low, sequencing costs
dominate. Instead of sequencing one individual at 303
depth, it might be possible to sequence seven to eight
individuals at 43 depth for approximately the same cost.
The 1000 Genomes Project13 has demonstrated that low-
coverage WGS can be used to discover and genotype
shared variants.
Low-depth sequencing relies on linkage-disequilibrium
(LD)-based methods that leverage information across indi-
viduals to improve the quality of variant detection and
estimated genotypes.20,22 In comparison to deep WGS,
low-depth sequencing is expected to result in higher
genotyping error rates, and this will result in lower power.
Initial simulation studies showed that low-depth
sequencing for a larger sample might be more powerful
than deep sequencing of fewer samples, both for variant
detection and subsequent disease association studies. For
example, Li et al.20 demonstrated that for variants with a
Box 1. Explanation of the Steps of the Data-Processing and Analysis Flow Chart for Sequencing-Based Association Studies in
Figure 1
Choose Analysis Plan and Platform
Rare-variant analysis requires careful planning related to sample and platform selection, quality control, statistical
analysis, results prioritization, and replication strategy.
Variant Calling and Quality Control
Variant detection and genotype calling from raw sequence data involve multiple steps; errors can occur in each step.
An important step is to investigate possible contamination of DNA samples. Contaminated samples often have un-
usually high levels of heterozygosity.36,139 Excluding contaminated samples from analysis or explicitly modeling
sample contamination during analysis can result in substantially more accurate genotype calls.
A number of measures can be calculated as broad indicators of the quality of genotype calls; these include read
depth, transition/transversion ratio, numbers of known and novel variants, and heterozygosity ratio. It is possible
to calculate additional measures, such as quality-control measures for each variant, including the quality score for
the assertion made in alternative alleles (QUAL), mapping quality, strand bias, haplotype scores, and so on. Methods
for machine learning have been developed to combine these scores.140
Bioinformatics Assay and Functional Annotation
Bioinformatics tools can be used to predict the impact of variants, such as synonymous, missense, nonsense and
splicing site variants, on amino acid sequence.141–145 Many of these tools also provide the predicted functional
impact (i.e., benign or deleterious) of coding variants. Recently, several methods have been developed to provide
functional annotation of noncoding variants.124,146 This information can be used in association analysis and result
interpretation.
Prioritization and Replication of Top Hits
After the identification of associated variants in the discovery phase, prioritization for replication and follow-up is
usuallymade on the basis of levels of statistical significance and, in some cases, apparent biological relevance. Because
the replication of rare-variant associations generally requires a large sample, replication studies should be carefully
designed to have adequate power. Strategies for the design of replication studies typically depend onmultiple factors,
including study budget and characteristics of the discovered variants, including MAFs and estimated effect sizes.MAF > 0.002, sequencing 3,000 samples at 43 has a power
similar to that of deep sequencing 2,000 individuals at 303
in single-variant association tests. Empirical studies are
now confirming these simulation-based findings.23
Exome Sequencing
Exome sequencing aims to sequence the 1%–2% of the
genome that codes for protein.24 It generally targets the
consensus coding sequence (of the CCDS Project),25 which
is ~30 million bases, but the precise regions targeted differ
by service providers. Many causal variants for Mendelian
disorders have been identified through exome sequencing.
DHODH (MIM 126064) for Miller syndrome (MIM
263750)26 and MLL2 (MIM 602113) for Kabuki syndrome
(MIM 147920)27 are prime examples.
An increasing number of studies now aim to use exome
sequencing to identify genes and variants associated with
complex diseases. Several large-scale exome sequencing
studies have been completed or are underway. For
example, the NHLBI ESP has sequenced the exomes of
~6,500 individuals to study phenotypes such as heart
attack, stroke, chronic obstructive pulmonary disease
(MIM 606963), blood lipid levels, blood pressure, and
obesity.28,29 The T2D-GENES Consortium has sequenced
the exomes of ~10,000 individuals across five ancestrygroups with the aim of identifying genetic variants associ-
ated with T2D and metabolic phenotypes. The UK10K
Project has sequenced the exomes of 6,000 individuals
with neurological disorders, obesity, or one of several rare
diseases to identify the genetic basis of these diseases.
Some low-frequency and rare disease-susceptibility vari-
ants have been identified by exome sequencing. Cruchaga
et al.30 demonstrated that rare variants in PLD3 (MIM
615698) are associated with late-onset Alzheimer disease
(LOAD) by sequencing 14 large LOAD-affected families,
and Lange et al.31 identified associations between low-
frequency and rare variants in PNPLA5 (MIM 611589)
and low-density lipoprotein cholesterol by sequencing
2,005 exomes.
Exome sequencing is typically carried out at a high
average depth; an average depth of 603–803 in targeted
regions can achieve a high probability of >203 coverage
in a large fraction (~80%–90%) of the protein-coding
regions.32 Because target-enrichment technology is imper-
fect, exome sequencing also produces some sequencing
reads in off-target regions. These off-target reads can be
useful for checking sequence quality and inferring popu-
lation structure.32–36
The primary limitation of exome sequencing is that it
captures genetic variation only in the exome. NoncodingThe American Journal of Human Genetics 95, 5–23, July 3, 2014 7
Table 1. Array and Sequencing Platforms for Rare-Variant Analysis
Advantage Disadvantage
High-depth WGS can identify nearly all variants in genome with
high confidence
is currently very expensive
Low-depth WGS is a cost-effective, useful approach for association
mapping
has limited accuracy for rare-variant identification and genotype
calling; compared to deep sequencing, is subject to power loss if
the same number of subjects is sequenced
Whole-exome sequencing can identify all exomic variants; is less expensive
than WGS
is limited to the exome
GWAS chip and imputation is inexpensive has lower accuracy for imputed rare variants
Exome chip (custom array) is much cheaper than exome sequencing provides limited coverage for very rare variants and for non-
Europeans; is limited to target regionsregions can play an important role in complex diseases and
traits. It has been shown that most GWAS loci lie in non-
coding regions.2 Recent results from the ENCODE Project
suggest that many noncoding regions might have impor-
tant biological function.37 Despite this limitation, the rela-
tive cost effectiveness and focus on a high-value portion of
the genome suggest that exome sequencing will remain an
important experimental approach for rare-variant studies
until WGS becomes less costly.
Targeted-Region Sequencing
Given the common variants that have been found to be
associated with complex diseases in GWASs, targeted-
region sequencing provides a cost-effective approach for
further investigation of high-priority regions of the
genome and has the potential to identify rare causal vari-
ants in GWAS loci. For example, Rivas et al.14 sequenced
56 candidate genes and discovered several low-frequency
and rare variants associated with Crohn disease, including
protective splicing variants in CARD9 (MIM 607212).
Similarly, Johansen et al.38 discovered large numbers of
rare variants in genes in GWAS loci among individuals
with hypertriglyceridemia. In contrast, other resequencing
studies have failed to identify disease-associated rare
variants,39,40 suggesting that few GWAS signals are driven
by nearby rare variants of strong effect. Large samples are
needed for identifying low-frequency and rare disease-
associated variants unless their effects are quite strong.
Custom Genotyping Arrays
Although current genotyping arrays do not assay enough
variants to capture more than a small fraction of all the
low-frequency and rare variants in a population, they do
provide a cost-effective alternative to sequencing of tar-
geted regions. Custom genotyping arrays, such as the
Metabochip41 for metabolic and cardiovascular disease
and the Immunochip42 for autoimmune and inflamma-
tory disease, were developed on the basis of high-priority
variants from GWASs and sequencing studies. These chips
include both common variants selected to replicate the
original GWAS signals and a selection of common and
low-frequency variants to enable detailed examination of
several hundred regions implicated in relevant traits by8 The American Journal of Human Genetics 95, 5–23, July 3, 2014GWASs, thereby allowing cost-effective fine mapping of
some low-frequency variants.
More recently, the Illumina and Affymetrix exome chips
have begun to provide an inexpensive array-based alterna-
tive to exome sequencing.32 The exome chips were devel-
oped on the basis of 12,000 sequenced exomes (mostly
of European ancestry), ~250,000 target nonsynonymous
variants, ~12,000 target splicing variants, and ~7,000
target stop-altering variants, as well as several additional
categories of variants, including GWAS-identified SNPs,
ancestry-informative markers, a grid of SNPs for imputa-
tion, mitochondrial SNPs, and human leukocyte antigen
tag SNPs.
Compared to exome sequencing, genotyping with
exome chips has important limitations. First, the ~12,000
exome-sequenced individuals onwhich the chip was based
are mostly Europeans. Hence, the current generation of
exome chips has more limited representation of low-fre-
quency and rare variants in non-Europeans.43 Second,
array-based technologies are limited in the range of vari-
ants they can target—for example, they require variants
flanked by short unique sequences with an appropriate
proportion of guanine and cytosine bases—and thus can
only successfully genotype 70%–80% of variants.
Because of its relatively low cost (103–203 less than
exome sequencing), the exome chip enables studies of
large numbers of individuals, substantially increasing sta-
tistical power for variants that are on the chip. The first
results of exome-chip-based studies are now being pub-
lished. For example, Huyghe et al.19 reported associations
between insulin processing and secretion and low-fre-
quency variants in SGSM2 (MIM 611418) and MADD
(MIM 231680) on the basis of exome-chip genotyping in
~8,000 Finnish individuals from the METSIM Study. There
are more studies underway, and we will learn the effective-
ness of exome array and the allelic architecture of complex
traits as their results become available.
Extreme-Phenotype Sampling
If the number of samples available for sequencing or gen-
otyping greatly exceeds a study budget, association power
can be improved by preferential selection of sequencing
individuals who are most likely to be informative. One
such approach is to sample individuals with extreme phe-
notypes in the reasonable hope that rare causal variants
will be enriched among them.11,44–47 In studies of quanti-
tative traits, one can select individuals with extreme trait
values after adjusting for known covariates. Alternatively,
in disease-focused studies, selecting individuals with
extreme phenotypes can often be done on the basis of
known risk factors.44 For example, in a case-control study
of T2D, one might sample affected individuals with
early-onset disease, low body mass index, and/or a family
history of T2D and control individuals who are old, obese,
and have no evidence of impaired glucose tolerance.
For quantitative traits, the required sample size for
extreme-phenotype sampling can be significantly smaller
than that for random sampling. For example, when
samples are selected from the upper and lower 10%
tails of the phenotype distribution, the number of in-
dividuals who must be sequenced for a given power can
often be reduced by more than half.45,46 A simple
approach for data analysis is to treat extreme phenotypes
as binary outcomes. Alternatively, extreme phenotypes
can be modeled to follow a truncated normal distribu-
tion.45,46 The latter approach is more powerful but might
be sensitive to the assumption of normality for the under-
lying continuous trait. A method for adjusting complex
extreme-phenotype sampling when one is interested in
studying multiple traits in the same set of subjects has
recently been developed.48
Despite its advantages over random sampling in terms of
power, extreme-phenotype sampling also has limitations.
Notably, the results might not be generalizable to the
underlying population and might be sensitive to outliers,
sampling bias, and the assumption of normality for the
underlying traits. If a complex trait is influenced by multi-
ple loci, extreme-phenotype sampling can reduce power to
detect loci with small effects.49 Power can also be affected if
variants in the two extremes have different directions of
effect.
Methods for Rare-Variant Association Testing
We focus in this section on providing an overview of asso-
ciation tests for rare variants. The analysis of rare variants is
more challenging than that of common variants. First, a
large sample size is needed for simply observing a rare
variant with a high probability. For example, sampling
alleles with a 0.5% or 0.05% frequency with 99% probabil-
ity requires sequencing at least 460 or 4,600 individuals,
respectively, even if perfect detection is assumed. Second,
standard single-variant association analysis is underpow-
ered to detect rare-variant associations. Numerous region-
or gene-based multimarker tests have been proposed in
recent years (Table 2); here, we review the general princi-
ples behind these tests.
Single-Variant Tests
In GWASs, the standard approach to testing for association
between genetic variants and complex traits is a single-variant test under an additive genetic model. The associa-
tion between each variant and a trait is typically evaluated
by linear regression for continuous traits and by logistic
regression for binary traits. GWAS single-variant tests
typically employ a significance threshold of 5 3 108,
corresponding to 5% genome-wide if ~1 million indepen-
dent association tests are performed.68 Thousands of
trait-associated loci have been identified with this simple
procedure. Single-variant tests can also identify association
with low-frequency variants if sample sizes are large
enough. For example, as noted earlier, single-variant tests
in a sample of ~8,000 individuals identified associations
between insulin processing and variants in SGSM2
(MAF ¼ 1.4%, p ¼ 8.7 3 1010) and MADD (MAF ¼
3.7%, p ¼ 7.6 3 1015).19
However, single-variant tests are less powerful for rare
variants than for common variants with identical effect
sizes.69 For example, with an odds ratio (OR) ¼ 1.4, the
sample sizes required to achieve 80% power are 6,400,
54,000, and 540,000 for a MAF ¼ 0.1, 0.01, and 0.001,
respectively, if one assumes 5% disease prevalence and a
significance level of 5 3 108. Because the number of
rare variants is much larger than the number of common
variants, more stringent significance levels might be
required, further reducing power.
Despite their limitations, single-variant tests are still a
useful tool for rare-variant analysis if the sample sizes
are large enough, the effects are very large, or the variants
are not too rare. Further, when combined with tools
such as quantile-quantile plots, genomic-control analysis,
and Manhattan plots, single-variant tests can be used
for evaluating data quality and identifying batch
effects or population stratification. It should be noted
that single-variant-based p value estimates based on stan-
dard regression methods might not be accurate if the
number of subjects with the variant is small,70 and
addressing this issue will require more methodological
development.
Gene- or Region-Based Aggregation Tests of Multiple Variants
Instead of testing each variant individually, aggregation
tests evaluate cumulative effects of multiple genetic
variants in a gene or region, increasing power when
multiple variants in the group are associated with a
given disease or trait. Numerous methods have been
developed, and we mainly review regression-based
methods that provide the ability to easily adjust for
covariates. We broadly categorize these methods into
five classes: burden tests, adaptive burden tests, vari-
ance-component tests, combined burden and variance-
component tests, and the exponential-combination (EC)
test (Table 2). These methods are based on varying
assumptions about the underlying genetic model, and
power for each test depends on the true disease model.
Because the true disease model is unknown and variable,
omnibus tests, such as the combined test discussed below,
are desirable.The American Journal of Human Genetics 95, 5–23, July 3, 2014 9
Table 2. Summary of Statistical Methods for Rare-Variant Association Testing
Description Methods Advantage Disadvantage Software Packagesa
Burden tests collapse rare variants
into genetic scores
ARIEL test,50 CAST,51
CMC method,52
MZ test,53 WSS54
are powerful when a
large proportion of
variants are causal and
effects are in the same
direction
lose power in the presence
of both trait-increasing and
trait-decreasing variants or a
small fraction of causal
variants
EPACTS, GRANVIL,
PLINK/SEQ, Rvtests,
SCORE-Seq, SKAT, VAT
Adaptive burden tests use data-adaptive
weights or thresholds
aSum,55 Step-up,56
EREC test,57 VT,58
KBAC method,59
RBT60
are more robust than
burden tests using fixed
weights or thresholds;
some tests can improve
result interpretation
are often computationally
intensive; VT requires the
same assumptions as burden
tests
EPACTS, KBAC,
PLINK/SEQ, Rvtests,
SCORE-Seq, VAT
Variance-component
tests
test variance of genetic
effects
SKAT,61 SSU test,62
C-alpha test63
are powerful in the
presence of both trait-
increasing and trait-
decreasing variants or a
small fraction of causal
variants
are less powerful than
burden tests when most
variants are causal and
effects are in the same
direction
EPACTS, PLINK/SEQ,
SCORE-Seq, SKAT, VAT
Combined tests combine burden and
variance-component
tests
SKAT-O,64 Fisher
method,65 MiST66
are more robust with
respect to the percentage
of causal variants and
the presence of both
trait-increasing and trait-
decreasing variants
can be slightly less
powerful than burden
or variance-component
tests if their assumptions
are largely held; some
methods (e.g., the
Fisher method) are
computationally intensive
EPACTS, PLINK/SEQ,
MiST, SKAT
EC test exponentially combines
score statistics
EC test67 is powerful when a very
small proportion of
variants are causal
is computationally
intensive; is less powerful
when a moderate or large
proportion of variants are
causal
no software is available
yet
Abbreviations are as follows: ARIEL, accumulation of rare variants integrated and extended locus-specific; aSum, data-adaptive sum test; CAST, cohort allelic sums
test; CMC, combined multivariate and collapsing; EC, exponential combination; EPACTS, efficient and parallelizable association container toolbox; EREC, esti-
mated regression coefficient; GRANVIL, gene- or region-based analysis of variants of intermediate and low frequency; KBAC, kernel-based adaptive cluster;
MiST, mixed-effects score test for continuous outcomes; MZ, Morris and Zeggini; RBT, replication-based test; Rvtests, rare-variant tests; SKAT, sequence kernel
association test; SSU, sum of squared score; VAT, variant association tools; VT, variable threshold; and WSS, weighted-sum statistic.
aMore information is given in Table 3.We first introduce the statistical model for various rare-
variant tests. Assume n subjects are sequenced in a region
withm variant sites. For subject i, let yi denote a phenotype
with mean mi, Xi ¼ (Xi1, ., Xiq)0 covariates, and Gi ¼
(Gi1,.,Gim)0 allele counts (zero, one, or two variant alleles)
for m variants of interest. We assume that yi follows a dis-
tribution in the quasi-likelihood family and consider the
following generalized linear model:71
hðmiÞ ¼ a0 þ a0Xi þ b0Gi; (Equation 1)
where h(m) ¼ m for a continuous trait, h(m) ¼ logit(m) for a
binary trait, a0 is an intercept, and a ¼ (a1,., aq)0 and
b ¼ (b1,., bm)0 are the regression coefficients for the cova-
riates Xi and allele counts Gi, respectively. We define the
score statistic of the marginal model for variant j as
Sj ¼
Xn
i¼1
Gij

yi  bmi;
where bmi is the estimatedmean of yi under the null hypoth-
esis (H0: b ¼ 0) and is obtained by application of the null
model hðmiÞ ¼ a0 þ a0Xi. Note that Sj is positive when
variant j is associated with increased disease risk or trait
values and negative when variant j is associated with
decreased risk or trait values.10 The American Journal of Human Genetics 95, 5–23, July 3, 2014Burden Tests
One class of aggregation tests can be termed burden tests:
they collapse information for multiple genetic variants
into a single genetic score50–54,72 and test for association
between this score and a trait. A simple approach summa-
rizes genotype information by counting the number of
minor alleles across all variants in the set. The summary
genetic score is then
Ci ¼
Xm
j¼1
wjGij; (Equation 2)
where wj is a threshold indicator or weight for variant j.
This approach is identical to assuming bj ¼ wjb in the
regression model in Equation 1 and testing H0: b ¼ 0 in
the simplified model hðmiÞ ¼ a0 þ a0Xi þ bCi. The corre-
sponding score statistic to test H0: b ¼ 0 is then
Qburden ¼
 Xm
j¼1
wjSj
!2
: (Equation 3)
A p value can be obtained by comparison to a chi-square
distribution with 1 degree of freedom.
The summary genetic score Ci can be defined to accom-
modate different assumptions about disease mechanism.
Table 3. List of Software Packages for Rare-Variant Association Tests
Name Type Methods Implemented URL
EPACTS stand alone burden, MB test, SKAT, SKAT-O, VT http://genome.sph.umich.edu/wiki/EPACTS
GRANVIL stand alone ARIEL, MZ http://www.well.ox.ac.uk/GRANVIL
MiST R-package SKAT, MiST http://cran.r-project.org/web/packages/MiST
PLINK/SEQ stand alone burden, C-alpha test, SKAT, SKAT-O, VT http://atgu.mgh.harvard.edu/plinkseq
Rvtests stand alone burden, VT, KBAC method, SKAT http://genome.sph.umich.edu/wiki/Rvtests
SCORE-Seq stand alone burden, SKAT, EREC test, VT, WSS http://dlin.web.unc.edu/software/score-seq
SKAT R-package burden, SKAT, SKAT-O http://www.hsph.harvard.edu/skat, http://cran.r-project.org/
web/packages/SKAT
VAT stand alone aSum, burden, C-alpha test, KBAC method, RBT, VT http://varianttools.sourceforge.net/Association/HomePage
Software Packages for Meta-analysis
MASS stand alone meta-analysis: burden, SKAT, VT http://dlin.web.unc.edu/software/mass
MetaSKAT R-package meta-analysis: burden, SKAT, SKAT-O http://www.hsph.harvard.edu/skat, http://cran.r-project.org/
web/packages/MetaSKAT
seqMeta R-package meta-analysis: burden, SKAT, SKAT-O http://cran.r-project.org/web/packages/seqMeta/
RAREMETAL stand alone meta-analysis: burden, SKAT, VT http://genome.sph.umich.edu/wiki/RAREMETAL
Abbreviations are as follows: ARIEL, accumulation of rare variants integrated and extended locus-specific; aSum, data-adaptive sum test; EPACTS, efficient and
parallelizable association container toolbox; EREC, estimated regression coefficient; GRANVIL, gene- or region-based analysis of variants of intermediate and
low frequency; KBAC, kernel-based adaptive cluster; MASS, meta-analysis of sequencing studies; MB, Madsen and Browning; MiST, mixed-effects score test
for continuous outcomes; RBT, replication-based test; Rvtests, rare-variant tests; SKAT, sequence kernel association test; VAT, variant association tools; VT, variable
threshold; and WSS, weighted-sum statistic.Instead of an additive genetic model, a dominant genetic
model can be used to compute genetic scores in which Ci
is the number of rare variants for which individual i carries
at least one copy of the minor allele (as in the MZ test53).
The cohort allelic sums test (CAST)51 assumes that the pres-
ence of any rare variant increases disease risk and sets the
genetic score Ci ¼ 0 given no minor alleles in a region and
Ci ¼ 1 otherwise. To focus on the rarer variants, we can
assign wj ¼ 1 when the MAF of variant j (MAFj) is smaller
than a prespecified threshold andwj¼ 0 otherwise. Alterna-
tively, a continuous weight function can be used to
upweight rare variants: Madsen and Browning54 proposed
wj ¼ 1 / [MAFj (1 MAFj)]1/2, and Wu et al.61 proposed the
family of beta densities wj ¼ beta(MAFj, a1, a2), which in-
cludes the Madsen and Browning weight as a special case.
In addition, bioinformatics information on functional ef-
fects of variants canbeused forweight construction (Box2).
Several burden methods have been proposed outside the
regression framework. For example, the combined multi-
variate and collapsing (CMC) method52 collapses rare var-
iants, as in the CAST, but in different MAF categories and
evaluates the joint effect of common and rare variants
through Hoteling’s t test. The weighted-sum test (WST)
of Madsen and Browning54 uses the Wilcoxon rank-sum
test and obtains p values by permutation.
The burden methods make a strong assumption that all
rare variants in a set are causal and associated with a trait
with the same direction and magnitude of effect (after
adjustment for the weights). Violation of these assump-
tions can result in a substantial loss of power.63,64,73TAdaptive Burden Tests
To address the limitations of the original burden tests, in-
vestigators have developed several adaptive methods that
are robust in the presence of null variants and allow for
both trait-increasing and trait-decreasing variants. Han
et al.55 developed a data-adaptive sum test (aSum) that first
estimates the direction of effect for each variant in a mar-
ginal model and then conducts the burden test with esti-
mated directions. It assigns wj ¼ 1 when bj is likely to
be negative and wj ¼ 1 otherwise. The approach requires
permutation to estimate p values. The step-up test56 refines
the procedure to use a model-selection framework that
assigns wj ¼ 0 when a variant is unlikely to be associated
by removing the variant from consideration.
The estimated regression coefficient (EREC) test57 uses a
more direct approach; it estimates a regression coefficient
of each variant and uses this as a weight. The test is based
on the expectation that the true regression coefficient bj is
an optimal weight to maximize power. Because bj esti-
mates are unstable when the minor allele count (MAC) is
small, the EREC test stabilizes the estimates by adding a
small constant to the estimated bj, which might reduce
the optimality of the EREC test. Given that asymptotic
approximation of the EREC test statistic is only accurate
for very large samples, it uses parametric bootstrap to esti-
mate p values.
The variable threshold (VT)58 is an adaptive extension
that selects optimal frequency thresholds for burden tests
of rare variants and estimates p values analytically or by
permutation. The kernel-based adaptive cluster (KBAC)he American Journal of Human Genetics 95, 5–23, July 3, 2014 11
Box 2. Issues that Need to Be Considered in Analysis
Which Variants to Use for Testing Associations
One of the important issues for gene- or region-based multimarker tests is selecting variants to be tested for the asso-
ciation. One can use all variants in the region or a subset of variants selected on the basis of MAF, impact on amino
acid sequence (e.g., nonsynonymous SNPs), or other sequence-based annotation. Bioinformatics methods have been
developed to predict functional roles of variants, and this information can also be used for refining subsets. For
example, PolyPhen-2143 predicts whether a variant is ‘‘benign,’’ ‘‘possibly damaging,’’ or ‘‘probably damaging.’’
One can carry out an association test with ‘‘possibly damaging’’ and ‘‘probably damaging’’ variants or only with
‘‘probably damaging’’ variants. Alternatively, one can assign weights for different class of variants by upweighting
functionally damaging or low-frequency variants. The existing bioinformatics methods are not perfect and can pro-
duce inaccurate predictions; hence, they should be considered as just one possible choice for refining subsets.
Which Association Test to Use
Multiple methods have been developed to test for disease association with sets of rare variants (Table 2). Relative per-
formance of these methods depends on the underlying and usually unknown disease architecture. If prior informa-
tion exists, one can choose the association test by incorporating this information. For example, if one expects that a
region has a large fraction of causal rare variants and the majority of them increase disease risk, burden tests are likely
to bemore powerful. If one expects that there exist both risk-increasing and risk-decreasing variants in a region or that
the majority of variants are null, variance-component tests are likely to be more powerful. If there is no prior infor-
mation, one can trymultiple methods and adjust p values by accounting for usingmultiple methods to avoid inflated
type I errors or use an omnibus test that is likely to have robust power across a range of disease models.
How to Test Nonexonic Regions
For whole-exome studies, it is natural to use a gene as an analysis unit. In whole-genome studies, however, it is less
clear how to properly define an analysis unit. There are several possible choices, such as functionally annotated or
evolutionarily conserved regions116,143,147 or even moving windows of a fixed size. The ENCODE Project37 provides
rich data for functional and regulatory elements in noncoding regions. As our understanding of noncoding regions
advances, we will develop better strategies for whole-genome data.method59 combines variant classification of nonrisk and
risk variants and association tests by using kernel-based
adaptive weighting. Ionita-Laza et al.60 proposed a WST
with an adaptive-weighting scheme to achieve robust
power in the presence of both protective and harmful
variants.
Adaptive burden tests are more robust than the original
burden methods because they require fewer assumptions
about the underlying genetic architecture at each locus.
Many adaptive tests are based on two-step procedures,
and the fact that some require estimation of regression
coefficients of individual variants in the first stage is often
difficult and unstable for rare variants. Most adaptive tests
require permutation to estimate p values and are hence
computationally intensive. Simulation studies73 suggest
that many adaptive tests have power similar to that of
variance-component and combined tests.
Variance-Component Tests
Another class of methods uses a variance-component test
within a random-effects model. These methods test for
association by evaluating the distribution of genetic effects
for a group of variants. Specifically, instead of aggregating
variants, variance-component tests, including the C-alpha
test,63 the sequence kernel association test (SKAT),61,74 and
the sum of squared score (SSU) test,62 evaluate the distribu-12 The American Journal of Human Genetics 95, 5–23, July 3, 2014tion of the aggregated score test statistics (possibly with
weights) of individual variants. SKAT casts the problem
in mixed models. In the absence of covariates, SKAT re-
duces to the C-alpha test. SKAT can also accommodate
SNP-SNP interactions.
Under model 1 (Equation 1), SKAT assumes that regres-
sion coefficients bj follow a distribution with mean 0 and
variance w2j t and tests the hypothesis H0: t ¼ 0 by
using a variance-component score test. The SKAT test
statistic
QSKAT ¼
Xm
j¼1
w2j S
2
j
is a weighted sum of squares of single-variant score statis-
tics Sj.
Because SKAT collapses S2j instead of Sj, as is done in
burden tests (Equation 3), SKAT is robust to groupings
that include both variants with positive effects and
variants with negative effects.QSKAT asymptotically follows
a mixture chi-square distribution; its p value can be
computed analytically quickly.75,76
For binary traits, large-sample-based p value calculations
can produce inaccurate type I errors rates when sample
sizes or total MACs are small. In these situations, false-pos-
itive rates can be deflated when the numbers of affected
and control individuals are equal and inflated when these
numbers are unequal. This is truenot only for SKATbut also
for any large-sample-based methods, including single-
variant and burden tests.70 To address this difficulty, Lee
et al.77 developed a moment-based method that adjusts
the asymptotic null distribution by using estimates of the
exact small-sample variance and kurtosis of the test statis-
tic.77 If the MAC is very low, even this adjustment might
not be sufficient, and obtaining accurate p value estimates
might require a permutation or bootstrap approach.Omnibus Tests that Combine Burden and Variance-Component
Tests
Variance-component tests are more powerful than burden
tests if a region has many noncausal variants or if the
causal variants have different directions of association. In
contrast, burden tests are more powerful than variance-
component tests if a region has a high proportion of causal
variants with the same direction of association. Both sce-
narios can arise; hence, it is desirable to combine these
two approaches.
Several methods have been proposed to combine burden
and variance-component tests. Derkach et al.65 proposed
using Fisher’s method78 to combine the p values of these
two tests and permutation to evaluate the significance of
the test. The Fisher statistic takes the form
Fisher ¼ 2logpSKAT 2logpburden;
where pSKAT and pBurden are p values obtained from SKAT
and burden tests, respectively. To increase computational
efficiency, Sun et al.66 modified the SKAT test statistic to
make it independent from the burden test statistic and
derived the asymptotic p value of the Fisher method.
Another approach is to use the data to adaptively com-
bine the SKAT and burden test statistics. Lee et al.64,77 pro-
posed a linear combination of SKAT and burden test
statistics:
Qr ¼ ð1 rÞQSKAT þ rQburden;0%r%1;
where the parameter r can be interpreted as a pairwise cor-
relation among the genetic-effect coefficients bj in Equa-
tion 1. Because in practice r is unlikely to be known,
they developed SKAT-O, an adaptive procedure that
approximates the test by using an optimal value of r esti-
mated with the minimum p value calculated over a grid
of rs. The asymptotic p value of SKAT-O can be calculated
with computationally efficient one-dimensional numeri-
cal integration.
Although combined tests achieve robust power by unify-
ing burden and variance-component tests, they can be less
powerful than either one of these tests if the assumptions
underlying one of these tests are largely true. However,
because we rarely have much prior information on genetic
architecture, combined tests are an attractive choice. It
should be noted that the naive approach of simply taking
theminimum p value of different methods generally yieldsTan inflated type I error rate. Proper p value calculations of
these omnibus tests need to counterbalance the effect of
searching for the optimal combination of statistics condi-
tional on the data, either analytically (e.g., as done in
SKAT-O) or empirically (e.g., with permutation).
The EC Test
The burden and variance-component tests are based on
linear and quadratic sums of Sj. The EC test
67 uses an expo-
nential sum of S2j , which is developed under a Bayesian
framework with a sparse alternative prior under the
assumption that only one variant in a gene or region is a
causal variant. The test statistic is
QEC ¼
Xm
j¼1
exp
 
S2j
2var

Sj
!:
Because the exponential function increases very rapidly
as S2j increases, the EC test can have higher power than
burden or variance-component tests when only a very
small proportion of variants are causal. However, the EC
test can be less powerful than burden and variance-compo-
nent tests when moderate or large proportions of variants
are causal. The null distribution of QEC is unknown, and so
permutations are required for estimating p values.
Comparison of Single-Variant and Gene- or Region-Based Tests
As previously mentioned, gene- and region-based tests are
designed to increase power by aggregating association sig-
nals across multiple rare variants. Indeed, if multiple asso-
ciated variants can be grouped together, these approaches
can result in substantial gains of power. However,
compared to single-variant-based tests, gene- and region-
based tests can lead to loss of power when one or a very
few of the variants in a gene are associated with the trait,
when many variants have no effect, and when causal var-
iants are low-frequency variants. For example, Cruchaga
et al.30 illustrated that gene-based tests can outperform
single-variant analyses. Specifically, these authors identi-
fied the association between Alzheimer disease and PLD3
by using a gene-based test p value of 1.4 3 1011, but no
single variant in the gene had a p value < 106. Many
rare variants in PLD3 were enriched among affected indi-
viduals, but their p values were not significant as a result
of their very low MAF; hence the gene-based test provided
better power by aggregating those rare variants. In study-
ing the association between blood lipids and BCAM and
CD300LG, Liu et al.79 found that single variants show clear
evidence of association but that gene-level tests show
weaker signal. This is most likely because these genes
contain a very small number of not-too-rare variants that
are associated with blood lipids.
Meta-analysis
Meta-analysis provides an effective way to combine data
from multiple studies.80–82 Rare-variant meta-analysis canhe American Journal of Human Genetics 95, 5–23, July 3, 2014 13
Box 3. Meta-analysis of Rare Variants
Summary Statistics from Each Study
A region-based rare-variant meta-analysis combines score statistics for individual variants, which can usually achieve
the same efficiency as joint analysis. Suppose that yki is the phenotype of the i
th individual (i ¼ 1,., nk) in the kth
study (k ¼ 1,., K), and Gki ¼ (Gki1, .,Gkim) is a vector of m genotypes in the region for the ith individual. For
meta-analysis, each study provides the following summary statistics:
1. MAF of each variant
2. Score statistics of each variant:
Skj ¼
Xnk
i¼1
Gkij

yki  bmki
3. Between-variant relationship matrix:
Fk ¼ G0kPkGk;
where Gk is a genotype matrix and Pk is a projection matrix accounting for the fact that the effects of covariates are
estimated.85 Note that the matrix Fk is a covariance matrix of genotype G up to a scalar factor when there is only an
intercept in Equation 1.
Meta-analysis Test Statistics
Under the assumption that study cohorts share the same set of causal variants with the same effect size, i.e., homo-
geneous (hom) genetic effects, the meta-analysis test statistics are
QmetaSKAT hom ¼
Xm
j¼1
 XK
k¼1
wkjSkj
!2
and
Qmetaburden ¼
 Xm
j¼1
XK
k¼1
wkjSkj
!2
for meta-analysis SKAT and burden tests, respectively. Here, wkj is a weight for variant j in study k.
85 If causal variants
or their effect sizes differ by cohorts, the test power can be improved if heterogeneous genetic effects are accounted
for. The meta-SKAT test statistic under heterogeneous (het) genetic effects85 is
QmetaSKAT het ¼
Xm
j¼1
XK
k¼1

wkjSkj
2
:
If studies are naturally grouped on the basis of ancestry, we can extend the methods by assuming that the genetic
effects for the same ancestry group are homogeneous and that those for different ancestries are heteroge-
neous.85,88 In addition to SKAT and burden tests, SKAT-O, VT, and conditional tests were also developed on the basis
of this score-statistic-based framework.79,85–87be carried out efficiently with simple study-specific sum-
mary statistics for the construction of rare-variant test sta-
tistics across large numbers of samples. Because detecting
rare-variant associations requires large sample sizes, we
expect that meta-analysis will play an important role in
rare-variant analysis. The simplest meta-analysis method
is to combine p values across studies by using Fisher’s or
Stouffer’s Z score methods.78,83,84 However, it is well
known that this approach is less powerful than joint
analysis of individual-level data and fixed-effects meta-
analysis.83
Recently, several groups developed rare-variant meta-
analysis frameworks that combine score statistics instead14 The American Journal of Human Genetics 95, 5–23, July 3, 2014of p values79,85–87 (Box 3). Key advantages that these
frameworks have over the traditional Wald-test-based
meta-analysis include computational efficiency (given
that only a null model shared between markers needs to
be fit) and numerical stability (because one does not
need to estimate regression coefficients and their SEs,
which is difficult for rare variants). Fixed-effects meta-
analysis can use individual-level data to achieve power
essentially identical to that of joint analysis.79,85,87 These
frameworks require that each study provide score statistics
for individual variants and also between-variant covari-
ance matrices that reflect region-specific LD information
among variants. These matrices later allow asymptotic
p values to be calculated. Burden tests, SKAT, SKAT-O, and
VT have all been developed in this score-statistic-based
meta-analysis framework. Conditional analyses, which
can assess whether rare-variant associations are shadows
of nearby significant common or rare variants, can also
be carried out in these frameworks.79
Genetic effects can be heterogeneous across studies,
and power can be increased if meta-analysis methods prop-
erly account for between-study heterogeneity.88,89 For
example, Morris88 developed a single-variant transethnic
meta-analysis method by using a Bayesian partition model
that takes into account the expected heterogeneity be-
tween diverse ancestry groups. Lee et al.85 developed a
rare-variant meta-analysis method that allows for different
levels of heterogeneity between studies or ancestry groups
by imposing varying correlation structure among genetic-
effect parameters.
Different sequencing platforms and strategies can pro-
duce different types of sequencing errors, artifacts, and
biases.90 Careful variant filtering and quality control are
important for avoiding the identification of associations
that are driven by between-platform heterogeneity. In
addition, we recommend systematic validation of any
findings that rely on combining data across different plat-
forms and/or sequencing strategies. Case-control imbal-
ances across different sequencing platforms might also
increase type I error rates, given that traditional large-
sample-based association tests of individual low-frequency
variants might not be well calibrated for case-control
imbalances.70 Addressing these issues will require more
research.
Other Analytic Issues for Rare-Variant Association
Studies
Population-Stratification Adjustment
Population stratification is a major confounding factor for
case-control association studies and can result in false-
positive associations.91,92 In GWASs, principal-component
analysis (PCA) and linear mixed models are commonly
used to adjust for population stratification.93 PCA is a
statistical method for finding directions of the largest
variability of the data.94 Principal components often
reflect the geographical distance of ancestral popula-
tions.95 The advantage of linear mixed models over PCA
is that they can adjust simultaneously for population strat-
ification, family structure, and cryptic relatedness.93,96 A
number of computationally efficient methods, including
EMMAX,96 Fast-LLM,97,98 and GEMMA,99 have been
developed to fit linear mixedmodels for quantitative traits.
Although both PCA andmixed-effects models have been
successful at adjusting for population stratification for
common variants, it is not yet clear whether these
methods will be effective for rare variants. PCA and mixed
models both assume a smooth distribution of MAFs over
geographical (or ancestry) space. Because rare variants are
often sharply localized, PCA and mixed models might
fail to correct for population stratification if the distribu-Ttion of disease risk is also sharply localized.100 Listgarten
et al.101 reported that Fast-LLM-Select, which uses a small
number of phenotype-selected variants to construct the
kinship matrix, can address the inflation of type I error
rates, but this approach can also reduce power substan-
tially when causal rare variants are spatially clustered.102
There have been several publications regarding the use of
PCA to correct for population stratification for rare-variant
association tests.103–105 PCA performance heavily depends
on the underlying risk distribution and population struc-
ture,100 and alternative strategies to using PCA as covari-
ates, such as using PCA to guide the matching of affected
and control individuals, might be useful.34 Moreover,
recent studies have shown that performing PCA with
only rare variants is no more effective in controlling for
population stratification than is performing PCA on the
basis of all, or only common, variants.103,104 If a large
pool of control individuals is available, it is possible to
use estimated ancestry scores to control for population
stratification.34 Off-target reads can also be used for
controlling for population stratification in targeted
sequencing studies.34
Genotype Imputation
Genotype imputation106 (or in silico genotyping) is a sta-
tistical technique for predicting genotypes at variants
that are not directly genotyped through the identification
of shared haplotype segments in densely typed reference
samples. A number of methods, including IMPUTE,107
Mach,108 and Beagle,109 have been developed for imputa-
tion. Recently, a prephasing strategy was developed to in-
crease computational efficiency of imputation with a large
number of reference samples.110
Development of sequencing technologies will result in a
large number of WGS reference samples, which could
enable the imputation of genotypes of low-frequency
and rare variants from existing GWAS samples without
additional experimental costs. Phase I of the 1000
Genomes Project provides a reference panel of 1,092
sequenced individuals. Across many sequencing projects,
we estimate that there are now>20,000 sequenced human
genomes, and many of these will be combined in a refer-
ence panel to facilitate imputation. In a recent example,
Auer et al.111 imputed more than 13,000 African American
samples by using the NHLBI ESP as a reference, pointing to
several novel low-frequency variants associated with blood
phenotypes, including missense variants associated with
white blood cell count in LCT (MIM 603202) and variants
associated with elevated platelet count in MPL (MIM
159530). Similarly, a rare variant associated with Alzheimer
disease (MIM 104300) in APP (MIM 104760)16 and a rare
frameshift variant associated with T2D in PDX1 (MIM
600733)112 were identified through large-scale imputation
with the use of WGS data of Icelanders as a reference.
Imputation accuracy decreases as MAF decreases, mak-
ing it challenging to impute very rare variants. Because
imputation accuracy increases with the number ofhe American Journal of Human Genetics 95, 5–23, July 3, 2014 15
reference individuals,113 the range of MAFs with suffi-
ciently accurate imputation accuracy should widen as
larger reference panels become available. With increasing
reference-panel sizes, we expect that imputation will
recover genotypes for low-frequency or moderately rare
variants with higher confidence.
Follow-Up Studies
Many sequencing experiments will not be able to convinc-
ingly associate rare variants with the trait of interest. Repli-
cation GWASs, which examine top-ranked variants in
additional samples, are an important strategy for identi-
fying true positive association. For rare-variant studies,
replication will be equally important and will often require
sequencing or genotyping large numbers of individuals.
Effective strategies for replication will depend on a study
budget and the discovered variants’ characteristics, in-
cluding MAFs and effect sizes.
If the follow-up studies target high-priority variants
identified in the discovery phase, targeted genotyping of
the selected variants in additional individuals can be
undertaken. For example, after deep sequencing 350
affected individuals and 350 control individuals in the dis-
covery phase, a genetic study of inflammatory bowel dis-
ease (MIM 266600) genotyped 70 protein-coding variants
(MAF ~ 0.001–0.05) in >16,000 individuals with Crohn
disease, >12,000 individuals with ulcerative colitis, and
>17,000 healthy control individuals.14 The study identi-
fied a protective splice variant in CARD9 (OR ¼ 0.29) and
additional disease-associated variants in IL18RAP (MIM
604509), CUL2 (MIM 603135), C1orf106, PTPN22 (MIM
600716), and MUC19 (MIM 612170).
When analysis of the discovery sample is based on func-
tional units rather than single variants, a more desirable
follow-up strategy could be to resequence the top func-
tional units, given that the association might be driven
by multiple rare variants, only a subset of which will
have been identified in the discovery sample. Although
follow-up resequencing is still more expensive than
follow-up genotyping, rapid advances in sequencing and
target-capture technologies114 will substantially reduce
the cost of the follow-up sequencing.
Note that replication of associations does not imply cau-
sality. For inferring the role of variants in disease mecha-
nism, careful consideration should be made for LD with
nearby variants and for the potential to detect false signals
that result from artifacts of population structure.
After identification of a robust association signal in dis-
covery and replication studies, experiments can be under-
taken to link the discovered variants or genes to molecular
or cellular functions. Various types of experiments can be
carried out depending on the nature of discovered variants:
in silico analysis using bioinformatic tools, analysis of
expression quantitative trait loci, in vitro protein assay,
chromatin-structure assay, and model-organism experi-
ments, to name a few. Reviews of this subject can be found
elsewhere.115,116 Such studies are often the logical next16 The American Journal of Human Genetics 95, 5–23, July 3, 2014step once clear statistical evidence of association has
been established and localized.
Estimation of Heritability Due to Significantly Associated
Low-Frequency and Rare Variants
It is of substantial interest to estimate the proportion of
heritability due to low-frequency and rare variants. To do
this, one can examine the numbers of common, low-fre-
quency, and rare variants in the genome, specify the prob-
ability that common and rare variants are causal, and
specify their effect sizes. We performed these calculations
under several scenarios by using the 6,500 exomes
sequenced by the NHLBI ESP to estimate the fraction of
variants in different frequency bins (Box 4).
We found that the actual proportion of heritability due
to low-frequency and rare variants varied from 18% to
84% across six scenarios (Box 4; Figure 2). Because power
to detect low-frequency- and rare-variant associations is
lower than the power to detect common-variant associa-
tions, the observed proportion of heritability due to low-
frequency and rare variants in finite samples might be
substantially smaller than the actual value if heritability
is calculated with only significantly associated variants,
say those reaching a ¼ 5 3 108, by the single-variant
test (Box 4; Figure 2).
For example, when rare-variant association studies are
carried out in a sample of 10,000 individuals, most rare
causal variants will show no significant association. In
this case, the apparent proportion of variance due to
rare variants might be <0.1%, even when rare variants
actually explain most of the heritability. As sample sizes
grow, more rare causal variants will be significantly
associated, and the estimated proportions of variance due
to rare alleles become closer to the true value. Still, even
after 1,000,000 individuals are studied, the estimated
proportion of variance due to rare variants remains
underestimated.
These results illustrate the possibility that even if rare
variants account for a large proportion of heritability, iden-
tifying them might require extremely large samples, a
finding that is consistent with several recent publica-
tions.117,118 Note that we could capture a higher fraction
of heritability if we used more powerful gene- or region-
based tests instead of a single-variant test, but the overall
qualitative conclusion would be similar. Currently, there
is no clear evidence as to which scenario represents the
true genetic architecture of common complex diseases,
and it is likely to vary across diseases and traits. As addi-
tional sequencing studies are performed, our understand-
ing will increase.
In this calculation, we focused on quantifying the herita-
bility explained by significantly associated low-frequency
and rare variants. If the goal is a more accurate estimation
of heritability, we might need to use all variants rather
than only significantly associated variants. For common
variants, mixed models have been successfully used to
calculate heritability due to all common variants,119 and
Box 4. Estimation of the Proportion of Heritability Due to Low-Frequency and Rare Variants
We considered several scenarios of the distribution of effect sizes. In the first scenario, common (MAF R 5%), low-
frequency (0.5%%MAF< 5%), and rare (MAF< 0.5%) variants were equally likely to be causal (r¼ 1), and their effect
sizes were identical regardless of MAF (Figure 2). The parameter r is a ratio of the probability that a rare or low-fre-
quency variant is causal to the probability that a common variant is causal. In the second and third scenarios, a
low-frequency or rare variant was four (r ¼ 4) or ten (r ¼ 10) times more likely to be causal. We also considered sce-
narios in which the effect sizes were assumed to be a decreasing function of MAF for low-frequency and rare variants.
In particular, regression coefficients in Equation 1 were modeled as b ¼ qjlog10MAFj∕ jlog100:05j when MAF% 0.05
and b ¼ q when MAF > 0.05, where the parameter q ¼ 0.183 provided power ¼ 0.8 at level a ¼ 5 3 108 when the
sample size was 50,000 and MAF was 0.05. For the first three scenarios of the constant effect size, we assumed that
b ¼ 0:183 regardless of MAFs. We estimated the observed proportion of heritability explained by low-frequency
and rare variants at different sample sizes ranging from 10,000 to 1,000,000 provided that the heritability was calcu-
lated with only significantly associated variants at level a ¼ 5 3 108. Specifically, we used the following formula:
PropH ¼
r
P
j;commonpjqj

1 qj

b2jP
j˛commonqj

1 qj

b2j þ r
P
j;commonqj

1 qj

b2j
;
where pj is an estimated power of single-variant test for variant j at a¼ 53 108, qj is theMAF of variant j, and the sum
is over the MAF spectrum of the NHLBI ESP data. Note that the denominator estimates the total heritability due to all
variants. The true population proportion of heritability explained by low-frequency and rare variants was computed
with pj ¼ 1.we expect that this approach can be extended to low-fre-
quency and rare variants.
Conclusions
In this review, we have focused on rare-variant association
analysis, especially on study design and association testing
methods. Because of the costs of deep WGS, several inter-
mediate, more affordable strategies for study design—
including targeted sequencing, exome sequencing, low-
depth WGS, and array-based genotyping—are currently
being used. Some of these, particularly array-based studies,
which routinely use imputation, will be enhanced further
as larger panels of sequenced samples become available.
We expect that these alternative designs will retain an
important role until the cost of WGS drops enough to
make them obsolete.
One strategy to improve power is to use publicly avail-
able data to augment the control set by selecting
ancestry-matched controls. This strategy has been success-
fully applied for identifying the association between
rare variants in CFH (MIM 134370) and age-related macu-
lar degeneration.33 Because different genotyping and
sequencing platforms have different genotyping qualities
and error rates, this approach should be used with extreme
caution; otherwise, it can severely increase false-positive
rates.120,121 We recommend using this strategy only in
the discovery phase to identify candidate genes or regions.
A single platform should be used for genotyping case and
control samples for replicating association signals.
Rare-variant studies are being conducted on diverse plat-
forms, and so one challenge is combining different types of
data. Indeed, different platforms have different characteris-Ttics, including coverage of rare variants and genotyping
error rates. We expect that meta-analysis methods can be
used for this purpose after proper variant filtering to pre-
vent artifacts, but more systematic research on the effects
of using diverse platforms on association tests is required.
Although the burden of many diseases, such as infec-
tious diseases, is substantially higher in Africa and South
America than in other continents, genetic epidemiologic
studies in these continents have been underrepresented.
Several recent efforts, such as the Human Heredity and
Health in Africa Initiative, have been made to increase
genetic research in Africa. These ongoing efforts to survey
genetic variation in African populations and to design
effective arrays for African-ancestry samples will help to
facilitate studies of these understudied populations.
Several approaches that we have discussed here would
have to be customized for studying these populations.
For example, more effective array-based approaches will
require a more extensive survey of low-frequency and
rare variants in samples of African and South American
ancestry. Likewise, imputation-based analyses will most
likely require larger reference panels of African-ancestry
samples to achieve the same level of accuracy as in the
European population13 because of higher genetic diversity
and lower LD levels in African populations.122,123 In these
populations, direct sequencing might be more attractive
for fine-mapping and association studies.123
Because of cost considerations, current rare-variant
studies largely focus on exome regions. We expect that
the focus will gradually extend as the cost of WGS de-
creases. Challenges for whole-genome rare-variant analysis
include limited available information for prioritizing andhe American Journal of Human Genetics 95, 5–23, July 3, 2014 17
Figure 2. Using Single-Variant Tests to
Estimate the Proportion of Heritability
Explained by Significantly Associated
Low-Frequency and Rare Variants
Dashed lines represent the true proportion
of heritability explained by low-frequency
and rare variants, and solid lines represent
the estimated (by single-variant tests)
observed proportion of heritability due to
significantly associated low-frequency and
rare variants at level a ¼ 5 3 108. From
top to bottom, the three curves correspond
to the situation when a low-frequency
(0.5%%MAF < 5%) or rare (MAF < 0.5%)
variant is ten timesmore (r¼10), four times
more (r ¼ 4), or equally (r ¼ 1) likely to be
causal than a common variant.
(A)Effect sizesof causalvariants areassumed
to be constant regardless of MAF: b ¼ q.
(B) Effect sizes of causal variants of rare or low frequency are assumed to be a decreasing function of MAF: b ¼ qjlog10MAFj∕ jlog100:05j.
The parameter q is set at q¼ 0.183, which provides power¼ 0.8 at level a¼ 53 108 when the sample size is 50,000 and theMAF is 0.05.annotating most likely functional variants, which is
important for grouping variants for multimarker tests
and interpreting results. Progress in annotating the func-
tional consequences of nonexome variants37,124 will facil-
itate future genome-wide sequencing-based association
studies.
We have provided a review of numerous recently devel-
oped methods for rare-variant association testing. Given
that the relative performance of these methods depends
on the underlying genetic architectures of complex traits,
it is difficult to have a test that is optimal for all scenarios.
Omnibus tests that combine different tests provide an
attractive alternative for balancing power and robustness.
When more is learned about genetic architectures of com-
plex diseases and traits, this knowledge can be incorpo-
rated in association tests to increase power and prioritize
variants for replication studies and functional analysis.
Because of space limitations, we have primarily focused
in this paper on population-based rare-variant association
studies. Family-based association studies provide an attrac-
tive and complementary approach for studying rare vari-
ants. Family-based studies can allow multiple copies of
rare variants to be sampled and are useful for studying de
novo mutations,125 and indeed, several methods of per-
forming rare-variant association tests in families have
been developed.126–130 Because family studies often have
much smaller sample sizes than population-based studies,
integrating information from population-based studies
and family-based studies can be useful in investigating
rare-variant effects.131 In addition to the frequentist
approaches we have primarily covered in this paper,
Bayesian methods can provide an alternative framework
for evaluating rare-variant association. Bayesian methods
can incorporate model uncertainty or prior information
to improve analysis power132,133 and provide insights
into the genetic architecture of traits by localizing causal
variants.134
As more large-scale sequencing studies are conducted,
more rare variants associated with disease and quantitative18 The American Journal of Human Genetics 95, 5–23, July 3, 2014traits will be discovered. Integrated analysis with other
types of ‘‘omic’’ data is increasingly carried out to facilitate
more powerful discovery and result interpretation and
to inform the functional roles of the discovered vari-
ants.135–138 These efforts will help us better understand
the genetic architecture of complex diseases. Integration
of sequence-based genetic and genomic data with environ-
mental and clinical data will facilitate a better translation
of molecular information in population and clinical
practice to advance disease prevention, intervention, and
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